B细胞恶性肿瘤治疗的进展与展望
Advances and Perspectives in the Treatment of B-Cell Malignancies.
作者信息
Cuenca Marta, Peperzak Victor
机构信息
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.
出版信息
Cancers (Basel). 2021 May 8;13(9):2266. doi: 10.3390/cancers13092266.
Abstract
B-cell malignancies arise from different stages of B-cell differentiation and constitute a heterogeneous group of cancers including B-cell lymphomas, B-cell leukemias, and plasma cell dyscrasias [...].
摘要
B细胞恶性肿瘤起源于B细胞分化的不同阶段，构成了一组异质性癌症，包括B细胞淋巴瘤、B细胞白血病和浆细胞异常增生症[...]。
相似文献
1
Advances and Perspectives in the Treatment of B-Cell Malignancies.B细胞恶性肿瘤治疗的进展与展望
Cancers (Basel). 2021 May 8;13(9):2266. doi: 10.3390/cancers13092266.
2
Long non-coding RNAs in B-cell malignancies: a comprehensive overview.B细胞恶性肿瘤中的长链非编码RNA：全面概述
Oncotarget. 2017 Apr 20;8(36):60605-60623. doi: 10.18632/oncotarget.17303. eCollection 2017 Sep 1.
3
Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives.原发性皮肤B细胞淋巴瘤的诊断与治疗：现状与展望
Cancers (Basel). 2020 Jun 8;12(6):1497. doi: 10.3390/cancers12061497.
4
The classification of lymphomas and leukemias.淋巴瘤和白血病的分类。
Chem Biol Interact. 2001 Jun 1;135-136:653-64. doi: 10.1016/s0009-2797(01)00201-0.
5
Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.Pax5在非霍奇金淋巴瘤和急性白血病中的表达。
J Korean Med Sci. 2003 Dec;18(6):804-8. doi: 10.3346/jkms.2003.18.6.804.
6
Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.人类Lyb-2同源物CD72是祖B细胞白血病的一个标志物。
Am J Hematol. 1992 Nov;41(3):151-8. doi: 10.1002/ajh.2830410303.
7
8
9
Characterization and classification of rat leukemias and lymphomas by membrane markers.通过膜标志物对大鼠白血病和淋巴瘤进行特征描述与分类。
Cancer Res. 1981 May;41(5):1938-42.
10
Pathology of T-cell lymphomas: diagnosis and biomarker discovery.T细胞淋巴瘤的病理学：诊断与生物标志物发现
Cancer Treat Res. 2015;165:51-95. doi: 10.1007/978-3-319-13150-4_3.
引用本文的文献
1
MicroRNA-196a increases apoptosis in B cells through downregulation of FOXO1.微小RNA-196a通过下调FOXO1增加B细胞凋亡。
Mol Cells. 2025 Jul;48(7):100223. doi: 10.1016/j.mocell.2025.100223. Epub 2025 May 20.
2
Causal association between B cell count and psoriasis using two-sample Mendelian randomization.采用两样本孟德尔随机化方法研究 B 细胞计数与银屑病之间的因果关系。
J Cell Mol Med. 2024 Sep;28(17):e70089. doi: 10.1111/jcmm.70089.
3
Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma.代谢组学：B细胞非霍奇金淋巴瘤诊断或预后的新时代。
Diagnostics (Basel). 2023 Feb 23;13(5):861. doi: 10.3390/diagnostics13050861.
4
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.重塑肿瘤微环境：免疫调节药物在 B 细胞肿瘤中的多功能性。
Front Immunol. 2022 Oct 12;13:1017990. doi: 10.3389/fimmu.2022.1017990. eCollection 2022.
5
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies.作为抗癌治疗递送平台的纳米载体：B细胞恶性肿瘤的生物学局限与前景
Pharmaceutics. 2022 Sep 17;14(9):1965. doi: 10.3390/pharmaceutics14091965.
本文引用的文献
1
Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma.血浆胸腺和活化调节趋化因子（TARC）在经典型霍奇金淋巴瘤中的生物学特性及临床适用性
Cancers (Basel). 2021 Feb 20;13(4):884. doi: 10.3390/cancers13040884.
2
Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.滤泡性淋巴瘤微环境：一个有待治疗干预的复杂网络。
Cancers (Basel). 2021 Feb 5;13(4):641. doi: 10.3390/cancers13040641.
3
Primary Pulmonary B-Cell Lymphoma: A Review and Update.原发性肺B细胞淋巴瘤：综述与更新
Cancers (Basel). 2021 Jan 22;13(3):415. doi: 10.3390/cancers13030415.
4
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.多发性骨髓瘤中复发性基因畸变的代谢效应
Cancers (Basel). 2021 Jan 21;13(3):396. doi: 10.3390/cancers13030396.
5
Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions.造血系统癌症与实体癌症及T细胞功能障碍：探寻异同
Cancers (Basel). 2021 Jan 14;13(2):284. doi: 10.3390/cancers13020284.
6
Immune-Checkpoint Inhibitors in B-Cell Lymphoma.B细胞淋巴瘤中的免疫检查点抑制剂
Cancers (Basel). 2021 Jan 8;13(2):214. doi: 10.3390/cancers13020214.
7
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.克服B细胞非霍奇金淋巴瘤中基于自体T细胞疗法的障碍
Cancers (Basel). 2020 Dec 18;12(12):3837. doi: 10.3390/cancers12123837.
8
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy.多发性骨髓瘤中的泛素化及类泛素修饰：生物学与治疗
Cancers (Basel). 2020 Dec 14;12(12):3764. doi: 10.3390/cancers12123764.
9
Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.复发性弥漫性大B细胞淋巴瘤的分子遗传学：对治疗耐药机制的洞察
Cancers (Basel). 2020 Nov 28;12(12):3553. doi: 10.3390/cancers12123553.
10
Risk and Response-Adapted Treatment in Multiple Myeloma.多发性骨髓瘤的风险与适应性治疗
Cancers (Basel). 2020 Nov 24;12(12):3497. doi: 10.3390/cancers12123497.
Zotero 插件